17 Mar 2023 07:00
Yourgene Health plc
("Yourgene", the "Group" or the "Company")
Directorate Change
Appointment of Interim Chief Financial Officer
Manchester, UK - 17 March 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that it has agreed that Barry Hextall, Chief Financial Officer ("CFO"), will step down from his role as a director to pursue other opportunities with immediate effect.
Barry, who has been with the Company for eight years, will provide an orderly handover over the next six months and will remain as Company Secretary until a full-time successor is appointed. Peter Charles, an experienced Interim CFO with broad cross sector experience, will take on the CFO role on a short-term basis, in a non-Board capacity. The process of recruiting a full-time CFO will begin immediately and it is expected to conclude in time for the full-time CFO to benefit from the agreed handover period.
Dr John Brown, Non-Executive Chairman, commented: "I would like to extend the Board's thanks to Barry for his contribution to Yourgene Health over the last eight years and his willingness to support an orderly handover. We wish him the very best for the future and look forward to updating shareholders further in due course."
This announcement contains inside information for the purposes of the UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgenehealth.com | |
Joanne Cross, Director of Marketing | ||
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | |
Liam Murray / Ludovico Lazzaretti | ||
| ||
Singer Capital Markets (Corporate Broker) | Tel: +44 (0)20 7496 3000 | |
Aubrey Powell / Tom Salvesen / George Tzimas | ||
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | |
Paul McManus / Alice Woodings / Lianne Applegarth | Mob: 07980 541 893 / 07407 804 654/ 07584 391 303 | |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit https://yourgenehealth.com/ and follow us on twitter @Yourgene_Health.